Background: Group A streptococcus (GAS) primarily colonizes the mucosal region of the
upper respiratory tract, slowly leading to systemic infections. Thus, GAS-specific antibody responses
are desirable at mucosal sites for early prevention against GAS colonization.
Methods: Herein, we developed a potent nanoliposomes-based delivery system for mucosally active
lipid core peptide (LCP)-based vaccines.
Results: Trimethyl chitosan (TMC)-coated liposomes that bore a B-cell epitope derived from GAS Mprotein,
stimulated potent epitope-specific mucosal and systemic antibody titres after only one boost
following intranasal immunization in Swiss outbred mice. The immune responses were durable even at
day 139 post-primary immunization.
Conclusion: The enhanced vaccine efficacy, lowered dose, and simple and cost-effective process of
producing the coated nanoliposomes should be particularly useful in developing potent peptide-based
vaccines to prevent infections at the mucosal sites.